CinCor Pharma CEO Marc de Garidel (Eric Piermont/AFP via Getty Images)
October 12, 2021 10:56 AM EDTUpdated 11:13 AM
Financing

Qui­et Cin­Cor Phar­ma makes some noise with $143M, new tri­al plans for blood pres­sure drug

Nicole DeFeudis

Editor

Cin­Cor Phar­ma has been fair­ly qui­et since emerg­ing in the hy­per­ten­sion space a cou­ple of years ago with a for­mer Roche pro­gram in tow. Not …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

A service from the Financial Times